SCHEMBL2448205

SCHEMBL2448205

CS(=O)(=O)Oc1ccc(N2CCN(S(C)(=O)=O)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
TSHR P16473 2/20 0.53
LMNA P02545 1/20 0.53
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
POLB P06746 1/20 0.50
MAPT P10636 6/20 0.48
GAA P10253 3/20 0.48
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
CYP2C9 P11712 1/20 0.46
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 3/20 0.46
GLA P06280 1/20 0.46
PKM P14618 1/20 0.46
HTT P42858 1/20 0.45
TP53 P04637 1/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2157251 0.85 TSHR (0.71) SMN1; SMN2TSHRLMNAMEN1KMT2A
SCHEMBL19615056 0.83 SMN1; SMN2 (0.53) SMN1; SMN2TSHRLMNAMEN1KMT2A
SCHEMBL2155738 0.81 NPSR1 (0.59) SMN1; SMN2TSHRLMNAMEN1KMT2A
SCHEMBL2155221 0.81 MAPT (0.58) SMN1; SMN2TSHRLMNAMEN1KMT2A
SCHEMBL8691411 0.80 ADRB1 (0.62) TSHRLMNAALDH1A1KDM4EHSD17B10
SCHEMBL7413492 0.80 GFER (0.58) SMN1; SMN2TSHRLMNAMEN1KMT2A
SCHEMBL82680 0.79 MEN1 (0.69) SMN1; SMN2TSHRLMNAMEN1KMT2A
SCHEMBL974007 0.77 POLB (0.54) SMN1; SMN2TSHRLMNAMEN1KMT2A
SCHEMBL1926789 0.77 MAPT (0.58) SMN1; SMN2TSHRLMNAMEN1KMT2A
SCHEMBL6152910 0.77 MAPT (0.58) SMN1; SMN2TSHRLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530477-B2 Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betaHSD1 SANOFI (FR) 2013-09-10 US disclosed
EP-2364311-B1 TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 SANOFI SA (FR) 2013-07-03 EP disclosed
US-20110294809-A1 TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 SANOFI-AVENTIS (FR) 2011-12-01 US disclosed
EP-2364311-A1 TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 SANOFI (FR) 2011-09-14 EP disclosed
WO-2010049635-A1 TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 SANOFI-AVENTIS (FR) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294809-A1 TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 HSD11B1, HSD17B1, HSD17B11 SMN1; SMN2 2994/4885TSHR 1524/4885LMNA 2460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.